Explanation for the choice of comparators {6b}
The primary objective of the study is to demonstrate the non-inferiority with respect to safety, tolerability and preliminary efficacy of TTV-guided immunosuppression compared to standard TAC dosing. Current evidence suggests an optimal TAC trough level target of 7 ng/ml for standard-risk kidney transplant recipients in the first year post-transplantation [